Expand DNLI Menu
DNLI MENU

DNLI Latest Press Releases

-- February 5, 2026 --

Denali Therapeutics Presents Enzyme TransportVehicle Progress Across Three Clinical Programs for Treatment of Lysosomal Storage Disorders at 2026 WORLDSymposium Globe Newswire 2:00 PM

-- February 2, 2026 --

Denali Therapeutics To Host Webcast Highlighting Presentations on Enzyme TransportVehicle Programs at the 2026 WORLDSymposium Globe Newswire 8:00 AM

-- January 29, 2026 --

Denali Therapeutics Announces Data Presentations on Enzyme TransportVehicle Programs for Hunter Syndrome, Sanfilippo Syndrome Type A and Pompe Disease at Upcoming 2026 WORLDSymposium Globe Newswire 4:00 PM

-- January 6, 2026 --

Denali Therapeutics Announces Key Anticipated Milestones and Priorities for 2026 Including Commercial Launch of Tividenofusp Alfa for Hunter Syndrome Globe Newswire 8:00 AM

-- December 30, 2025 --

The New England Journal of Medicine Publishes Phase 1/2 Study of Denali Therapeutics' Tividenofusp Alfa (DNL310) for Hunter Syndrome (MPS II) Globe Newswire 8:00 AM

-- December 10, 2025 --

Denali Therapeutics Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants Globe Newswire 12:14 AM

-- December 9, 2025 --

Denali Therapeutics Announces Proposed Offering of Common Stock and Pre-Funded Warrants Globe Newswire 4:01 PM

-- December 4, 2025 --

Royalty Pharma and Denali Therapeutics Announce $275 Million Royalty Funding Agreement Globe Newswire 7:10 AM
Denali Therapeutics and Royalty Pharma Announce $275 Million Royalty Funding Agreement Globe Newswire 7:00 AM

-- November 6, 2025 --

Denali Therapeutics Reports Third Quarter 2025 Financial Results and Business Highlights Globe Newswire 4:01 PM
Denali Therapeutics Announces Board and Executive Leadership Updates Globe Newswire 4:00 PM

-- October 13, 2025 --

Denali Therapeutics Announces FDA Review Extension of BLA for Tividenofusp Alfa for the Treatment of MPS II (Hunter Syndrome) Globe Newswire 4:01 PM
Market Data Delayed 15 Minutes